CurrentColorado Rocky Mountain Health PlansPolicy 2026T0587X

Pharmacogenetic (PGx) Multi-Gene Panel Testing

This policy addresses the medical necessity and coverage rationale for pharmacogenetic multi-gene panel testing (panels of five or more genes) and specific molecular signature testing (PrismRA) for drug response, as applied to UnitedHealthcare Commercial and Individual Exchange benefit plans.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyPharmacogenetic (PGx) Multi-Gene Panel Testing

Policy CodePolicy 2026T0587X

Change TypeTemplate Update (administrative)

Effective DateJan 1, 2026

Next Review Date

Key ActionWhen ordering or documenting pharmacogenetic multigene panels or PrismRA testing, verify member-specific benefits, document clinical rationale and test limitations, and anticipate prior authorization or coverage denial risk given the current limited evidence.

SourceLink

POLICY UPDATE CHANGES

Created shared policy version to support application to Oxford plan membership and archived previous policy versions 2025T0587W and LABORATORY 023.23.

>=5Minimum genes defining a Multi-Gene Panel

5+Volume of summarized evidence

2026T0587XPolicy identifier

very low–limitedOverall evidence quality for several indications

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

39.6%PrismRA observed 24‑week ACR50 response

62%Providers reporting insurance-related barriers to follow recommendations

Coverage determinations

Coverage Rationale - Multi-Gene Panels

Covered when ALL of the following are met:

ALL of the following

Pharmacogenetic Multi-Gene Panels (five or more genes) for evaluation of drug-metabolizer status>= 5 genes
Defined as multigene tests that typically use next-generation sequencing and include five or more genes
Insufficient evidence of efficacy exists to demonstrate clinical utility
Therefore these tests are considered unproven and not medically necessary for any indication

Coverage Rationale - PrismRA molecular signature test

Covered when ALL of the following are met:

ALL of the following

Use of the PrismRA molecular signature test to evaluate likelihood of inadequate response to anti-TNF therapies for rheumatoid arthritis
Insufficient evidence of efficacy
Resulting coverage stance: unproven and not medically necessary>= 11.8

Evidence conclusions by clinical area

Covered when ANY of the following evidence-summary conclusions apply:

ANY of the following

Psychiatric indications: Some RCTs and reviews report improvements in response/remission or secondary endpoints at later follow-up and in certain subgroups (e.g., inadequately controlled patients), but primary outcomes at early timepoints are often not statistically different.
References subgroup and timing-specific outcomes
Cardiovascular disease/PCI: Evidence is limited; simulations and cohort data suggest potential opportunities for genotype-guided prescribing but high-quality outcome studies demonstrating improved clinical outcomes are lacking.
Anthracycline-induced cardiotoxicity (ACT)/chemotherapy-induced cardiotoxicity (CIC): Emerging genetic associations and predictive models exist but evidence certainty is low; additional prospective, ethnically diverse validation is required.
Uncertain predictive validity and need for diverse validation

Summary of Clinical Evidence and Conclusions

Summary statements of clinical evidence, model findings, limitations, and guideline positions:

ALL of the following

PrismRA performance metrics: reported positive predictive value ~89.8% and specificity ~86.8% (Mellors et al.); PrismRA score >= 11.8 used to identify likely poor responders.
Decision-analytic modeling conclusions: models suggest PrismRA-guided therapy could increase proportion achieving ACR50 at 12 months (example: modeled increase from 44% to 57%), but models assume full provider adherence and lack sensitivity analyses.
Limitations noted
- Studies are nonrandomized, nonblinded, limited racial/ethnic diversity, potential test laboratory affiliation bias
- Validation lacks randomized controlled trial data and comparator groups without testing

Representative procedure and billing codes

Representative CPT/PLA Codes referenced (panels and pharmacogenomic panels)CPT/PLANot Covered

0029U	Drug metabolism targeted sequence analysis (list of genes example: CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12777823)
0173U	Psychiatry genomic analysis panel, variant analysis of 14 genes
0175U	Psychiatry genomic analysis panel, variant analysis of 15 genes
0345U	Psychiatry genomic analysis panel, variant analysis of 15 genes, including CYP2D6 del/dup analysis
0347U	Drug metabolism 16 gene report with variant analysis and phenotypes
0348U	Drug metabolism 25 gene report with variant analysis and phenotypes
0349U	Drug metabolism 27 gene report with variant analysis including phenotypes and impacted gene-drug interactions
0350U	Drug metabolism 27 gene report with variant analysis and phenotypes
0392U	Drug metabolism (depression, anxiety, ADHD) variant analysis of 16 genes including CYP2D6 del/dup analysis
0411U	Psychiatry genomic analysis panel, 15 genes including CYP2D6 del/dup analysis

1–10 of 21

1/3

Actions, documentation & billing guidance for providers

Documentation Required

Reference and coding guidance

Providers should reference the list of applicable procedure codes when submitting claims; listing a code does not imply coverage. Benefit coverage for services is determined by the member-specific benefit plan document and applicable laws.

0029U
0173U
0175U
0345U
0347U
0348U
0349U
0350U
0392U
0411U
0419U
0423U
0434U
0438U
0460U
0461U

Clinical and evidence background

Pharmacogenetic testing evaluates how inherited genetic variation can influence an individual’s response to medications, with the stated aim of informing drug selection and dosing to improve efficacy or reduce adverse effects. Targeted testing of a single gene (or a small number of genes, e.g., 2–3 genes for warfarin) is commonly used when a specific drug decision is being considered; by contrast, laboratories have developed Multi-Gene Panels that test five or more genes simultaneously to provide preemptive information about many potential drug–gene interactions across therapeutic areas (definition per policy: multi-gene panels = ≥ five genes).

The policy reviewed multiple types of evidence to assess clinical utility for multigene pharmacogenetic (PGx) testing, including randomized controlled trials (RCTs), systematic reviews and meta-analyses, health-technology assessments, decision-analytic modeling, cohort and real-world observational studies, and clinical utility/ molecular test assessments (e.g., Hayes evaluations). While some RCTs and meta-analyses report early or subgroup improvements (for example, faster response or higher response/remission rates in certain depression trials at 8–12 weeks), other high-quality studies show limited or no durable benefit on primary endpoints or on longer-term outcomes. Trials such as PREPARE (a 12-gene pragmatic study) demonstrated reductions in adverse drug reactions in some populations, and multiple meta-analyses synthesize RCT data showing modest short-term improvements in psychiatric outcomes, but overall findings are mixed and context-dependent.

Important limitations of the evidence base are recurrent across clinical areas: study heterogeneity (varied gene content and proprietary algorithms across marketed panels), frequent lack of blinding of clinicians and/or participants in trials, short durations of follow-up in many studies (commonly 8–12 weeks), limited racial/ethnic diversity in study cohorts, potential conflicts of interest or industry involvement in several publications, and reliance on proprietary decision-support algorithms that differ between tests. These limitations reduce certainty about generalizability and the magnitude of clinical benefit for routine use of broad multigene panels.

For proprietary molecular signature classifiers such as PrismRA (a Scipher Medicine MSRC intended to predict nonresponse to anti‑TNF therapy in rheumatoid arthritis), the policy summarizes observational and modeling data suggesting potential to influence prescribing and improve response in selected cohorts (for example, reported positive predictive values near reported estimates and modeled increases in ACR50 in simulated cohorts). However, available studies are nonrandomized or cohort-based, often nonblinded, limited in size and diversity, and subject to potential test‑developer bias; randomized controlled validation and larger independent prospective studies are lacking, and decision models frequently assume full provider adherence and limited sensitivity analyses.

Defined terms

Definitions

PGxPharmacogenomics — genetic testing to predict drug response or adverse effects.

PrismRA / MSRCMolecular Signature Response Classifier — a proprietary test (Scipher Medicine) intended to predict response/nonresponse to anti-TNF therapy in rheumatoid arthritis.

Multi-Gene PanelGenetic tests that typically use next-generation sequencing to test multiple genes simultaneously; also called multigene test, multiple-gene panel test, and multiple-gene test.

TAUTreatment as usual (control arm in randomized trials).

CDAIClinical Disease Activity Index — a measure for rheumatoid arthritis disease activity.

HAMD-17 / HAM-AHamilton Rating Scale for Depression (17-item) / Hamilton Rating Scale for Anxiety — clinician-administered symptom scales.

Policy updates

01/01/2026clarifiedLatest

Template Update — Created a shared policy version to support application to Oxford plan membership and archived prior policy versions 2025T0587W and LABORATORY 023.23.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyPharmacogenetic (PGx) Multi-Gene Panel Testing

Policy CodePolicy 2026T0587X

Change TypeTemplate Update (administrative)

Effective DateJan 1, 2026

Next Review Date

SourceLink

On This Page

Pain management and opioid therapy: Evidence evolving with mixed results — some small RCTs and systematic reviews show reductions in opioid use or improved outcomes in selected trials, but overall evidence is limited, heterogeneous, and insufficient to broadly support multigene PGx panel testing for pain.

Rheumatoid arthritis (PrismRA / MSRC): Limited to very-low-quality evidence overall; cohort and observational data suggest MSRC/PrismRA may inform therapy selection and be associated with improved response when used to guide therapy, but studies are nonrandomized, potentially biased, and require larger independent validation.

Performance metrics reported in cohorts/observational studies

Longer-term data required for persistence, treatment patterns, and disease burden

Guideline/consensus positions

ACR: identifies need for biomarkers to predict DMARD response; PrismRA not specifically addressed
CPIC: provides actionable gene-drug guidelines (e.g., CYP2D6, CYP2C19) but does not recommend multigene panels of >=5 genes as a class
AACAP: recommends avoiding PGx testing to select psychotropic medications in children/adolescents
ISPG: supports CYP2D6 and CYP2C19 testing for psychotropics and HLA testing for carbamazepine/oxcarbazepine; cautions about unvalidated panels
NCCN (cancer pain): PGx testing may be considered when concern for toxicity or lack of analgesic response; panel testing not specifically addressed
VA/DoD (MDD): evidence insufficient to recommend for or against PGx testing

Overall conclusion: Broad pharmacogenetic multigene panel testing lacks sufficient high-quality evidence to support generalized clinical efficacy claims; targeted single-gene tests and CPIC-recommended gene-drug pairs remain the primary actionable evidence base.

Documentation Required

Use evidence and test-specific claims cautiously

Clinicians should interpret results from multigene pharmacogenomic (PGx) panels and proprietary molecular signature tests cautiously because evidence across indications is limited, heterogeneous, and of variable quality; testing should not be assumed standard of care until higher-quality prospective validation is available.

Prior Authorization

Potential need for prior authorization (implicit)

Payers may require prior authorization and documentation of the clinical rationale when ordering multigene panels (≥5 genes) or proprietary molecular signature tests given that routine use is not supported by high‑quality evidence for several indications.

Denial Risk

High denial risk for routine panel testing

Ordering broad multigene PGx panels for routine prediction of chemotherapy cardiotoxicity, general pain management, or as a standard pre-prescription test for opioids/analgesics carries a high risk of coverage denial because the policy considers these uses unproven and not medically necessary based on current evidence limitations.

Documentation Required

Consider clinical context and test limitations

When using PrismRA or PGx panel results to guide therapy, document the clinical rationale, note the limitations of the evidence (e.g., nonrandomized data, limited diversity, potential bias), and record the specific intended therapy change that the test influenced.

Prior Authorization

Insurance-related barriers may affect adherence to test recommendations

Anticipate and document payer-related barriers when implementing PrismRA-guided therapy or deviating from standard care, since providers commonly cited insurance-related issues as a reason for not following PrismRA recommendations.

Documentation Required

Reference member-specific benefit plan

Always reference the member-specific benefit plan document when determining coverage, because the terms of the member-specific plan may differ from this standard policy and, in the event of conflict, the member plan governs.

Documentation Required

Check federal/state mandates and Medicare guidance

Before applying this policy, verify the member plan and any applicable federal or state mandates; Medicare Advantage application may differ and MAOs may make their own determinations in the absence of NCD/LCD guidance.

Given the mixed results and quality concerns, the policy concludes that routine use of pharmacogenetic Multi-Gene Panels (≥ 5 genes) and tests like PrismRA is not supported as medically necessary for general clinical indications. The evidence is most supportive when focused on well-established single gene–drug pairs (for which CPIC guidance or product labeling provide actionable recommendations), whereas broad panel-based approaches and proprietary algorithms require further high-quality, blinded, and ethnically diverse prospective validation with longer follow-up to establish consistent clinical utility.

Policy thresholds

Multi-Gene Panel definition thresholdfive or more genes

Minimum genes for CPT 81418 referenceat least 6 genes (includes CYP2C19, CYP2D6, CYP2D6 CNV)

PrismRA score threshold for predicting poor response to anti-TNF>= 11.8

ACR50 response>= 50% improvement

ACR50American College of Rheumatology criteria for 50% improvement in rheumatoid arthritis disease activity.

b/tsDMARDBiologic or targeted synthetic disease-modifying antirheumatic drug.

Pharmacogenetic (PGx) Multi-Gene Panel Testing

Coverage determinations

Representative procedure and billing codes

Actions, documentation & billing guidance for providers

Clinical and evidence background

Defined terms

Other policies to read with this document

Policy updates